Stocks To Buy Now Blog

Stocks on Radar

Friendable Inc. (FDBL) Addresses Churn in the Music Streaming Industry by Offering Fan Pass Live and Branded Products to Enhance Listener Experience

  • Churn occurs when subscribers sign up for a streaming service and immediately cancel once the current season or event is over, but re-sign up when something new catches their attention
  • Fan Pass Live offers subscribers a new type of experience that revolves around the life of their favorite artists and the ability to see them on-demand
  • The global music streaming industry was valued at $29.49 billion in 2021 and is expected to reach $103.07 billion by 2030, growing at a CAGR of 14.7%
For companies competing in the music and video streaming industry, personalization is becoming a key contributor to earning higher subscriber retention rates. Churn has always been a problem in the landscape, with subscribers signing up for subscription services but leaving the platforms once their need was fulfilled and signing up again when a new season or event occurs. With video streaming platforms introducing algorithms that “recommend” what you should watch next, Friendable (OTC: FDBL), a mobile technology company focused on its Fan Pass Live artist platform, is introducing a new way to engage and retain subscribers through its Fan Pass Live branded offering. The Fan Pass Live artist platform proactively supports artists and provides a personalized experience for fans who subscribe to its music platform, including:
  • An exclusive look into the artists’ lives
  • The ability to browse for upcoming events (online and in-person)
  • Backstage access before, during, and after an event
  • A single dashboard where fans can view notifications, discussions, and new artists
  • Real-time interactions through livestream performances
  • Exclusive interviews and one-on-one videos
  • A behind-the-scenes look at music videos and photoshoots
  • Access to exclusive artist merchandise
For $2.99 per month, fans gain access to a growing catalog of artists across multiple musical genres, including pop, rock, indie, jazz, and more. Additional charges apply for VIP and Pay-Per-View performances, with artists earning 100% revenue from ticket sales and fan tips. Yearly rates are also available for fans subscribing to the music platform, offering a discount from the monthly price. At the beginning of 2022, Friendable announced the successful acquisition of Artist Republik and FeaturedX, completing its offering as a 360-degree offering for artists and adding additional opportunities for fans. Now, artists can produce, distribute, and market their music across additional platforms, in addition to creating musical collaborations with other artists with ease. The current artist contest being held by the company is the Artist Republik Song of the Summer contest. All entries have been submitted and narrowed down. Although the artists are in control of their music, fan voting controls the winner of the $1,000 prize in each genre category. In the coming months, Fan Pass Live’s artist platform will offer artists and fans the opportunity to experience music in a new realm – with NFTs and Metaverse performances. As the digital landscape of music evolves, Friendable is at the forefront of bringing new technology to the music industry. The global music streaming market size reached $29.49 billion in 2021 and is expected to grow at a CAGR of 14.7%, resulting in $103.07 billion by 2030. The industry’s growth is expected to occur due to the increased interest in digital platforms and the use of smart devices, which enhance the experience for artists and fans alike. Despite the churn that occurs for subscription services, platforms are still popular for their ability to personalize the music experience and the ease of use for connectivity, allowing for hassle-free apps and browser experiences (https://ibn.fm/Sh6we). Fan Pass Live personalizes the music experience for the fans by taking them on a journey with their favorite artists through the livestream experience, merchandise, and the ability to browse new and upcoming artists. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Supporting Best Farming Practices to Reduce Agriculture-Related Greenhouse Gas Emissions, Ammonia Emissions

  • FuelPositive is a growth-stage company focused on developing clean energy solutions such as its onsite, containerized green ammonia production system
  • FuelPositive understands the impact of ammonia emissions on the environment and biodiversity and is supporting best farming practices that are geared toward eliminating the production, storage, and spreading of manure, a significant source of the emissions
  • The company’s system generates green ammonia, which can be injected deep into the soil, reducing the possibility of volatilization (the process through which gaseous ammonia is emitted into the atmosphere)
  • The company is working towards helping farmers solve on-farm nitrogen emissions, having already tackled fertilizer production carbon emissions
A 2022 study that sought to expose the weekly cycle of atmospheric ammonia over the main agricultural source regions in Europe – Belgium, the Netherlands, northwest Germany, Po Valley, Brittany, and the Ebro Valley –  showed that the amount of ammonia peaked during the two primary (manure) fertilization periods in spring and summer (https://ibn.fm/MR3tZ). Ammonia, NH3, is primarily used around the world as fertilizer because it is rich in nitrogen, which is essential for growing healthy crops. Manure contains ammonia, that is naturally produced. Ammonia can also be manufactured and used as mineral/synthetic fertilizer. The findings of the study are consistent with analysis by fertilizer manufacturer Yara, which observes that 94% of all ammonia emissions in the European Union (“EU”) block result from agriculture, with the remaining 6% originating from industrial applications, road transportation, and waste handling. Of the ammonia emissions generated from agriculture, livestock manure accounts for 75%, while mineral/synthetic fertilizer applications account for 22% (https://ibn.fm/sYaEu). With these emissions being linked to deleterious impacts on biodiversity – including soil acidification, direct damage to leaves and toxification of plants, and altered susceptibility to weather events – reducing the rate and levels of emissions is paramount if biodiversity is to be protected. According to a report by the Royal Society and RAND Europe (https://ibn.fm/i5qc5), ammonia emissions can, in fact, be reduced by managing the production, storage, and spreading of manure. And FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on developing clean energy solutions, suggests that emission reductions can also be realized by manufacturing green ammonia without the use of fossil fuels and injecting it deep into the ground. FuelPositive’s flagship product, an onsite, containerized green ammonia production system, uses renewable electricity to synthesize hydrogen from water and nitrogen from the air before combining the molecules in a converter to form green ammonia. In this way, and given there are no carbon emissions related to production, FuelPositive is looking to reduce the carbon emissions linked to the agriculture sector’s use of ammonia. About 80% of all grey ammonia, which is produced through a fossil-fuel energy-intensive process responsible for about 1.8% of the world’s carbon dioxide emissions, is used in the agricultural setting. In addition to reducing the carbon emissions from ammonia production, FuelPositive is looking to do more by supporting best farming practices. The company acknowledges that ammonia, even that produced by its green ammonia system, must be handled with care to prevent environmental damage. This is why farmers receive training in its safe handling and proper application. But many farmers often mismanage the production, storage, and spreading of manure, a natural source of ammonia. “Farmers spray liquid manure on the ground, which releases gaseous ammonia into the atmosphere and creates a situation where rain and runoff move a tremendous amount of highly nitrogen-intense materials (nitrous oxides or NOx) into waterways and water tables, causing significant detrimental effect (pollution) to air and water quality,” FuelPositive’s website reads (https://ibn.fm/Urjw7). Additionally, farmers’ storage practices are wanting as they often store the manure in piles and or ponds that release gaseous ammonia into the atmosphere through a process known as volatilization. FuelPositive aims to solve this problem by eliminating the carbon emissions associated with the manufacturing of ammonia used for fertilizer, and applying it through deep injection into the ground, providing the most efficient transfer of nitrogen into the soil, with the least impact from nitrous oxides. The company acknowledges the problems posed by nitrous oxides and other nitrogen-related emissions and is working with its agriculture sector advisors and scientists to address this issue and help farmers develop one implement best practices to manage and ultimately eliminate these emissions. Undeterred by the fact that nitrous oxides and other nitrogen-related emissions are not just emitted by grey or green ammonia but also by all types of nitrogen fertilizers, whether synthetic or organic, FuelPositive seeks to ultimately identify how to use its fertilizer in the least polluting way. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

With a Fresh $31 Million in Tow, EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) to Ramp RNG Supply Across Canada

  • EverGen owns and operates Western Canada’s original renewable natural gas facility and is expanding nationwide
  • EverGen already has existing offtake agreements with FortisBC, part of the nation’s largest private utility
  • EverGen recently signed a new loan agreement providing $31 million for expansion at its flagship projects in B.C.
Renewable Natural Gas, or RNG, is instrumental in meeting emissions targets by taking methane-producing organic feedstock like disposed food, sewage water, and animal waste and converting it into a carbon-neutral products, including an alternative to traditional natural gas. FortisBC Energy is a climate control steward in Western Canada, ramping supply agreements with companies such as EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) (https://ibn.fm/TIUfH) to keep up with demand from a waiting list of customers as part of a broader plan to see British Columbia reach net zero emissions by 2050. EverGen is an emerging RNG supply leader and organics processor in Canada creating a cluster of facilities to leverage both the attractive organic feedstock tip fees and long-term RNG pricing available. EverGen’s first three owned and operated facilities – Net Zero Waste Abbotsford (“NZWA”), Sea to Sky Soils (“SSS”), Fraser Valley Biogas (“FVB”) – are in southern British Columbia, with the company expanding into Alberta and Ontario in 2022 to capitalize on new opportunities in strategic jurisdictions. EverGen has long-term offtake agreements with FortisBC for the RNG produced at Net Zero Waste Abbottsford, GrowTEC, and Fraser Valley Biogas. FortisBC Energy and FortisBC, units of Newfoundland-based Fortis Inc., Canada’s biggest private utility, showed in May to have helped their customers reduce pollution by about 578,000 metric tons of carbon dioxide equivalent in 2021. That’s equivalent to a year’s worth of emissions from approximately 177,000 gasoline-powered cars. It was made possible by FortisBC increasing its RNG supply by 184% from 2020-2021. FortisBC expects to triple supply again in 2022 to be approaching 4 petajoules of RNG supply contracted to keep feeding into its pipelines. The company estimates its contracted supply is enough to replace natural gas in approximately 43,750 homes in British Columbia. EverGen has goals of its own, including estimates to generate $50-$60 million in revenue annually by achieving production of 2 million gigajoules per year of RNG. The pathway to reach these targets involves expansion projects in B.C., development projects in Alberta and Ontario, and additional target acquisitions. Thanks to a new agreement, EverGen has $31 million to move forward. Earlier this month, EverGen signed a term sheet with its existing lender, Scotiabank subsidiary Roynat Capital, and Export Development Canada for a $31 million senior term loan to support the planned upgrade and construction work at FVB ($15 million) and NZWA ($16 million). FVB, which is distinguished as the first producing RNG facility in Western Canada, combines anaerobic digestion and biogas upgrading to produce RNG, primarily by converting agricultural waste from local dairy farms. Expansion at the project is slated to begin this quarter and be completed in the first quarter of 2023, effectively doubling capacity and RNG production to approximately 120,000 gigajoules per year initially and then 160,000 gigajoules annually by mid-2023. A new offtake agreement, with existing partner FortisBC, is being finalized. NZWA is an organic waste conversion facility that primarily processes inbound organics, yard waste and biosolids for a contracted tipping fee, and produces high-quality organic compost and soils for farmers, gardeners, and developers. The capital expansion will add anaerobic digestion capabilities to produce biogas, which will then be upgraded to RNG to feed into FortisBC’s gas network under an existing 20-year off-take agreement. This project, expect to cost between $32-$35 million, has been in the works and experienced delays owning to the extensive flooding in the region last year compounded by regulatory delays related to the COVID-19 pandemic. Expectations are for groundbreaking to commence sometime in the next 12 months with a construction timeline of 6-8 months. Once complete, RNG output at NZWA is targeted at 180,000 gigajoules per year. The new production will be added to RNG totals from eastern projects. EverGen has 67% ownership of GrowTEC, an operating farm-scale biogas facility near Lethbridge, Alberta that will be expanded from 80,000 gigajoules of RNG annually to 140,000 gigajoules. The production is already under contract to supply FortisBC. That’s about 480,000 gigajoules annually from FVB, NZWA and GrowTEC. EverGen also owns 50% of a three-facility project dubbed “Project Radius” in the lower, Great Lakes region of Ontario. These three projects are thought to be constructed throughout 2023 and 2024 and be some of the larger RNG facilities in the country, with each expected to produce at least 550,000 gigajoules of RNG per year for an aggregate of approximately 1.7 million gigajoules, or nearly 2.2 million gigajoules corporate-wide for EverGen. For more information, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

AROYA Crop Steering Expertise and Technology Provides Data-Driven Insights, Automation and Competitive Advantage for Successful Harvests

For cannabis operators, crop steering directs how their plants grow as well as their literal shape. Knowing how and when to manipulate light, climate and irrigation – the three foundational components of crop steering – is essential to balancing high yields and high quality. Why do successful growers – from small craft farmers to the largest multistate operators – use data-driven and automated crop steering solutions? Because even the slightest adjustments to any number of factors can have huge effects on grows. Data is the lifeblood of a plant growers, providing the intelligence to track how and when plants change from phase to phase and eliminate unknown variables, perfecting each run. The AROYA cultivation solution combines innovative hardware and software to deliver actionable insights from data, improving quality and yield – predictably and at scale. With data-driven insights into each aspect of harvests, operators are empowered with the knowledge to not only increase yield per square foot, but also establish and employ repeatable best practices that ensure consistent quality. Identifying and adapting to various cues – from light, climate, and irrigation – encourages plants to produce bigger flowers with higher quality as well as finish getting their DNA out into the world before they die in an evolutionary selection process known simply by “stress.” Generative stress is targeted intentional environmental pressure that encourages a plant’s behavior by focusing on reproductive parts. This not only finishes filling up space for future generations, but also removes unwanted elements like pests. In crop steering, this leads plants to produce almost double the count of bud sites. Also of note is that as every specific cultivar has its own feeding needs, automated crop steering maintains the balance between being too vegetative or too generative in terms of quality and yield. Despite the increasing use of technology across the industry, many craft and independent farmers are sticking with their tried-and-true manual methods, like physically pouring run-off into milliliter cups, taking notes, and running tests by hand. And to their credit, they’re having success. Unfortunately, failing to embrace cultivation and production technology will be their demise. In addition to competition from larger operators, many smaller outfits have gone all-in with crop steering, advanced drying and analytics. Using crop steering tech provides access to easy-to-use, comprehensive tools to collect, analyze, and understand plants on a new level. As a result, they can bring out the most sought-out features of each cultivar. The ability to consistently deliver the highest-quality products to market is the key to keeping and growing your customer base. AROYA’s Cannabis Production Platform leverages crop steering solutions and cutting-edge IoT sensor technology to help plants grow better in different environments. Combining patented telemetry systems and software turns data into insights for each phase of growth. Access to insights and analyses like rising terpenes, fluctuating THC levels, and total cannabinoids brings out the best of each strain. Hitting specific water content, moisture levels, and drying with precision brings the most out of cultivars. For large operators like STIIIZY, AROYA makes it a lot easier to manage multiple facilities and assign tasks remotely, and to know if at any time a grow is operating outside of certain thresholds. Crop steering enables scalability and growth for STIIIZY, the third best-selling brand in the United States and the number one brand in California – the largest cannabis market in the world. Analyzing historical records for each stage optimizes growth across all areas, which is how operators like STIIIZY consistently produce runs with higher yields while maintaining production levels and quality. AROYA’s technology enhances cultivation practices – which are repeatable and are implemented in every STIIIZY facility. Sean Oganesyan, Senior Vice President of Cultivation with STIIIZY, credits the company’s success to data intelligence real-time insights secured from AROYA’s Cannabis Cultivation and Production Platform, which allows him to manage multiple facilities from a single location. “The concept of sensor density is important, as more sensors deployed across our grows ensures better results and data-driven decisions that eliminate unknown variables. I don’t like variables. I dot all my i’s and cross all my t’s – that’s my military background. I need answers, I need to know exactly what’s going on, I need to be in full control of a situation, and that gave me control. That’s why I’m comfortably sitting here and talking to you today. I’m not going around somewhere in a plane or flying to some different state because somebody messed something up in my irrigation.” “The communication with the AROYA team is fluid; we both understood what we must gain from each other, and this helps STIIIZY bring good products to the market.” AROYA’s IoT sensors installed at customer facilities not only observes – but also enables digital interactions between stakeholders involved in every part of the cannabis cultivation process – from selecting nutrients to use during vegetative periods down to dietary instructions once flowerheads start forming on branches. Cultivators rely on giving plants an ideal amount of light each day; the AROYA platform provides access to this data, delivering insights on exactly what percentiles lights need to stay at with specific plants and the amount of coverage within each room, allowing growers to adjust lighting quicker using data-driven decisions. With BACnet access to AROYA with STIIIZY’s fully controlled system, Oganesyan can communicate with his controls with AROYAs sensors to make decisions for plants based on real-time data and recipes assigned to specific cultivars, adjusting things like irrigation based on EC readings in a plant’s substrate. “AROYA gives me full control of my irrigation cycles,” said Oganesyan. “I have the full analytics team behind it continuously monitoring multiple locations. All my grows are literally run through my headquarters in downtown Los Angeles.” Operators must be able to account for everything that’s going on inside their facilities, and even if you have the tightest controls, there’s still going to be variables that are just inherent to the cannabis industry, such as plant variation. Oganesyan touted AROYA’s differentiators and superior technology among the biggest selling points for selecting AROYA over other systems. “If you got a company that makes sensors and you got all the other companies buying those sensors, white labeling those sensors and want to put their name on it, I just go straight to the source.” ABOUT AROYA AROYA is a cannabis production platform that combines industry-leading hardware and software to help cultivators increase yield, scale operations, and achieve consistent quality. Based in Pullman, Washington, and a division of METER Group, Inc., AROYA optimizes and demystifies the entire cannabis production process from seed to package. For additional information, please visit AROYA.io. Third-Party Content The STBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the STBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of STBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and STBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by STBN providing you with this internet portal that makes accessible to you the ability to view third party content through the STBN site, STBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. STBN expressly disclaims liability relating to such third-party content. STBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, STBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.stockstobuynow.com/disclaimer/.

Hillcrest Energy Technologies Ltd.’s (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA) Power Inverter Platform Boosts Performance and Efficiency, Enables Multiple End-Uses

  • Hillcrest’s power inverter technology platform to offer efficiency and performance improvements
  • Hillcrest inverter technology platform can be applied at nearly every stage of the electric ecosystem
Electrification is playing a prominent role in the global transition from fossil fuels to sustainable energy sources. As energy costs rise amid increased demand, Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) (FRA: 7HIA.F) holds a vital key that unlocks performance and efficiency improvements throughout the entire electrification ecosystem. Hillcrest’s first application for its inverter technology is focused on the growing EV market. Hillcrest’s SiC high-efficiency traction inverter technology converts the DC output from the batteries into AC input used by the motor. The expected benefits of Hillcrest’s traction inverter have been confirmed via testing and shared in a technical white paper published earlier in 2022:
  • Significant efficiency gains – 99%+ inverter efficiency
  • Increased power density targeting 50 kW/L+
  • Significantly increased motor efficiency
  • Lower stress on mechanical and electrical parts/reliability
  • Improved thermal management
Applications of Hillcrest’s technology extend beyond EV operation and charging to grid-connected power generation and energy storage systems. For example, the company’s inverter technology can convert wind turbine generation AC output to deliver power to a battery or deploy it to the grid. Power inverters can also be used in solar power generation by converting DC output from the photovoltaic panels into AC power that flows into the home, back to the battery, or out to the grid. Other applications include power conversion for energy storage systems and EV DC fast chargers. For these non-motorized applications, Hillcrest’s inverter technology has the potential to provide significant efficiency gains, better power quality and grid stability, lower stress on mechanical and electrical parts, and improved thermal management. “We set out to be a market leader in developing and deploying next-generation energy solutions,” said Ari Berger, Hillcrest CTO. “As technology-forward experts, we are uniquely positioned to execute to our vision and deliver high-efficiency inverter solutions that have the potential to revolutionize global electrification. We’ve already achieved inverter efficiencies exceeding 99% at switching frequencies up to 60 kHz – enabling further efficiency enhancements in the overall system, such as electric motors.  These accomplishments exceed any other inverter solutions we’ve seen on the market thus far. Moving forward, we will continue to strive for more groundbreaking improvements as we develop additional applications.” Based in Vancouver, British Columbia, Hillcrest develops transformative power conversion technologies and control system solutions for next-generation electrical systems. As the world moves forward on the path to sustainable energy sources, the company is favorably positioned to provide the keys that unlock performance and efficiency across the entire electrification value chain. For more information, visit the company’s website at www.HillcrestEnergy.tech. NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF

Laredo Oil Inc. (LRDC) Progressing Toward Drilling as 2023 Oil Demand Projected to Increase

  • OPEC releases “bullish” forecast for oil demand moving into 2023
  • Healthy global economic growth, improvements in geopolitical developments and containment of COVID-19 in China contribute to positive projection
  • LRDC has leased 37,900 mineral acres in the Western Williston Basin of Montana
Despite a slowing economy and worries of a recession, the oil and gas industry has rebounded strongly throughout 2021, with oil prices reaching their highest levels in six years, a recent Deloitte report noted (https://ibn.fm/aobNZ); OPEC’s recent bullish 2023 forecast indicates that upward trend may continue. That’s good news for Laredo Oil (OTC: LRDC), an oil exploration and production company that is working to start drilling in Montana. “OPEC expects global oil demand to rise in 2023 but at a slower pace than 2022, the producer group said in its first forecast for next year, citing still robust economic growth and progress in containing COVID-19 in China,” reported Reuters (https://ibn.fm/wqA7A). “In a monthly report on Tuesday, the Organization of the Petroleum Exporting Countries (‘OPEC’) said it expects demand to rise by 2.7 million barrels per day (‘bpd’), or 2.7%, in 2023. It left this year’s growth forecast unchanged at 3.36 million bpd.” Reuters noted that oil use has “rebounded from the pandemic-induced slump in 2020 and is set to exceed 2019 levels this year. The outlook for 2023 suggests a strain on supplies could persist as growth in non-OPEC output, which has been hit by Russian losses, is expected to lag the rise in demand.” However, Reuters noted that OPEC pointed to “2023 expectations for healthy global economic growth amidst improvements in geopolitical developments, combined with expected improvements in the containment of COVID-19 in China” as factors in its projected positive oil forecast. Laredo Oil’s primary focus is on acquiring, developing and operating undervalued conventional oil and gas properties. The company is also engaged in the acquisition and development of select mature oil fields that are suitable for its proprietary Enhanced Oil Recovery (“EOR”) methods. The company leased 37,900 mineral acres in the Western Williston Basin of Montana at favorable prices during the most recent down cycle and continues to take leases in the area. For more information, visit the company’s website at www.Laredo-Oil.com. NOTE TO INVESTORS: The latest news and updates relating to LRDC are available in the company’s newsroom at https://ibn.fm/LRDC

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

  • Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
  • The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
  • Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
  • The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program
As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://ibn.fm/moh25), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies. “Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of expectations that investors can use in their analysis,” the August 11 press release reads (https://ibn.fm/yrv8k). One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (“FDA”), there are five steps to the drug development process: Discovery and Development, Preclinical Research, Clinical Research, FDA Drug Review, and, finally, FDA Post-Market Drug Safety Monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the Discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment, with favorable results to boot. The company’s first advanced human clinical study (“HCS”) for hypertension, conducted in 2018, for example, showed that DehydraTECH drug delivery technology delivered 317% more CBD to the blood at 30 minutes. Later HCS’s evidenced rapid and sustained drop in blood pressure (HYPER-H21-1), up to a 23% average reduction in overnight blood pressure and reduced arterial stiffness (HYPER-H21-2), and a 41% overall reduction in pulmonary artery systolic pressure (“PASP”) in male subjects (HYPER-H21-3). Lexaria is set to announce results from its fourth HCS – HYPER-H21-4 – in Q4 2022 (https://ibn.fm/N5sjD). If the HYPER-H21-4 study were registered with the FDA, Lexaria notes, it would possibly be a Phase 1B or 2A study. This information lends color to the company’s valuation going by a guide prepared by Bay Bridge Bio, which notes that a company’s valuation increases as its drug development progresses from Phase 1 through Phase 3. For example, at the start of a Phase I trial, a biotech company’s valuation would be $88 million, a figure that would then rise to $248 million at the start of Phase 2 study, finally eclipsing the $1 billion mark to settle at $1.119 billion when the Phase III trial begins. The figures increase further following an FDA approval of the drug candidate. Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, the company’s accelerated drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course. The pharmaceutical industry is rife with examples of such possibilities. In March, for example, Pfizer Inc. (NYSE: PFE) completed the acquisition of clinical-stage company Arena Pharmaceuticals for a total consideration of $6.7 billion. At the time of the acquisition, Arena was expecting results for its Phase 3 trial undertaken to evaluate the safety and efficacy of the etrasimod drug candidate in patients with active ulcerative colitis (https://ibn.fm/uI4b5). As a December 2021 report by accounting firm PwC notes, big pharma is set to spend anywhere between $5 billion and $15 billion and, in some cases, as much as $50 billion in 2022 to purchase promising biotech companies and their IP, as they seek to bring on board in new drugs that can become serious revenue generators (https://ibn.fm/zCx4o). Such acquisitions attest that biotech companies with little to no revenue can still be worth billions. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

  • Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain’s connectivity patterns
  • CYBN is leading the industry in developing proprietary psychedelic-based therapeutics
  • The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder
The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders and improving patient outcomes. Psilocybin is undergoing a transformation. Numerous studies have reported positive findings using psilocybin “for treating depression as well as smoking and alcohol addiction, and for reducing anxiety in the terminally ill,” reported Scientific America (https://ibn.fm/Wx1Cv). “Ongoing and planned studies are testing the drug for conditions that include opioid dependence, PTSD and anorexia nervosa. This scientific interest, plus growing social acceptance, is contributing to legal changes in cities across the U.S.” The article provided a quick overview of the history of the substance, noting that “after a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S. as a Schedule I substance. The article quoted David Nutt, a neuropsychopharmacologist at Imperial College London, as saying: “It’s the worst censorship of research in history.” This “censorship” appears to be coming to an end as Nutt and others are leading a “research resurgence” focused on how psilocybin changes the brain’s connectivity patterns, including reducing connections within the usual networks while increasing links between less connected regions. “Just this year, a study showed that treatment involving psilocybin led to sustained network alterations, which seemed to correlate with reduced depression symptoms,” the article observed. “Two organizations are beginning final rounds of trials for psilocybin’s use for depression, which could lead to the substance’s first approval by the U.S. Food and Drug Administration.” Cybin is heavily involved in this resurgence of research. The company is leading the industry in developing proprietary psychedelic-based therapeutics, with a pipeline featuring three psychedelic molecules —CYB003, CYB004 and CYB005 — that are derived from CYBN’s novel drug-discovery platform (https://ibn.fm/4ZfwT). Cybin’s lead investigational molecule, CYB003, is a deuterated psilocybin analog derived from psilocybin, which is part of a family of molecules called indolamines that includes more common neurotransmitters, such as serotonin. The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect and potentially better tolerability for an overall better outcome for patients. CYB003 has the potential to effectively treat major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) and is currently being evaluated in a phase 1/2a clinical trial. A deuterated dimethyltryptamine (“DMT”), CYB004 has been shown to exert its psychedelic effects by activating the 5-HT2A receptor. In its natural form, DMT is rapidly metabolized in the body, unstable and not orally bioavailable. However, preclinical studies indicate that the deuterated DMT can overcome these limitations and provide increased oral and pulmonary bioavailability, faster onset with lower doses, less patient variability, and better dose titration for fewer side effects and longer-acting desensitization of the serotonergic receptors. The company reports that CYB004, which is currently in a phase 1 in-human study, has the potential to effectively treat anxiety disorders. The company’s third substance is CYB005, which is a discovery-phase phenethylamine derivative with the potential to effectively treat neuroinflammation and psychiatric conditions. CYB005 is in preclinical development. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

Golden Matrix Group Inc. (NASDAQ: GMGI) Scores Big Q3 Win on International Expansion

  • GMGI sets new bar for quarterly revenue, topping $9 million for first time
  • The company currently has a string of 15 consecutive profitable quarters
  • Golden Matrix is growing through international M&A activity and launching gaming products, including a new highly anticipated eSports platform
Tech stocks have rallied since the tech-laden Nasdaq hit a nearly two-year low in June. Most of the first half of the year was dominated by geopolitical drama, and international upheaval fueling recession concerns amid spiking inflation. None of that stopped Golden Matrix Group (NASDAQ: GMGI) from having its best revenue quarter ever, spearheaded by horizontal and vertical growth. Golden Matrix, a provider of turnkey and white label gaming platforms and content, hasn’t filed its 10-Q quarterly report with the Securities and Exchange Commission yet, but did provide some color to investors on its third quarter of fiscal 2022, which ran from May-July. The Las Vegas-based company logged record revenues exceeding $9 million in the quarter, an improvement of approximately 177% from $3.25 million in the comparable quarter of fiscal 2021. Meaningful progress in both its flagship business-to-business (“B2B”) division and new business-to-consumer (“B2C”) division undergirded the jump in revenue. GMGI CEO Brian Goodman called the record quarter “even more impressive when considering the impact of global economic headwinds and an unfavorable exchange rate throughout the quarter.” The strength of the U.S. dollar is important to Golden Matrix as the bulk of its customers are overseas, particularly Asia-Pacific as far as B2B clients. Golden Matrix has chosen not to foray into the byzantine U.S. market, with its software designed to decline requests coming from within the country to maintain strict compliance with U.S. law. At the end of the quarter, GMGI had about 635 operators and approximately 6.5 million registered users across all its traditional B2B gaming platforms. Internationally, GMGI’s GM-X System is the industry standard as a configurable and scalable gaming platform providing access to over 10,000 games from dozens of providers along with sophisticated analytics, retention tools, loyalty features, and more. Through GM-X, Golden Matrix offers an array of games, including slots, table games, live games, and sports. The company is also planning on expanding into the burgeoning eSports that is growing at a stunning 22% compound annual growth rate on its way to an estimated $12.5 billion by 2030. The new GMGI B2B eSports platform is expected to make its debut any time now. Record quarterly revenue has also been spurred on by Golden Matrix taking an 80 percent stake in RKings, the United Kingdom-based owner of a popular skill tournament platform operated in the U.K. and Ireland. RKings gives players an opportunity to win a bevy of products from jewelry to golf clubs to exotic cars and vacations. In the latest quarter, RKings’ B2C competitions engaged more than 46,000 new registered users. The company didn’t provide insight into EBITDA or net income in its recent news release, but investors surely will be looking forward to the regulatory filings to see if the string of profitable quarters – currently standing at 15 – continues. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

  • Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head
  • Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients
  • The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy
  • PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by the body, helping it to target the area where it is needed most with minimal expression in the blood’s circulation system
Medical solutions innovator Odyssey Health (OTC: ODYY) is preparing to launch Phase II clinical trial testing of its novel brain concussion therapy following successful outcomes in examining its drug’s safety. Odyssey’s PRV-002 combines a synthetic neurosteroid with an intranasal applicator device to deliver the drug in such a way that it will be taken up into the brain with minimal circulation through the blood system. The drug is lipophilic, which helps it to cross the blood-brain barrier where it needs to go to rapidly eliminate swelling and oxidative stress in the brain in order to maintain proper blood flow to critical parts of the organ. Odyssey Health has completed a series of lab animal tests involving the company’s proprietary solution and announced this month the successful completion of the first cohort of the multiple ascending dose portion of its Phase I clinical trial analyzing safety of the drug in human volunteers. The company is finishing up the final stage of its Phase I trial that involves administering high doses of the drug to human patients. Phase II will take a hard look at the efficacy of the drug product by looking at specific outcome measures. (https://ibn.fm/x4TP7). Concussions, also known medically as mild traumatic brain injury, or mTBI, have come to be taken more seriously in the general public in recent years, particularly as professional athletes have acknowledged a need to prioritize their recovery from significant head impacts over a desire to remain competitive. NASCAR driver Kurt Busch became one of the latest to acknowledge head injury concerns when he chose to sit out multiple races until he could be assured he was mentally as well as physically recovered from a qualifying round crash in late July. “Brain injury recovery doesn’t always take a linear path. I’ve been feeling well in my recovery, but this week I pushed to get my heart rate and body in a race simulation type environment, and it’s clear I’m not ready to be back in the race car,” Busch said when he announced he’d miss a fourth race (https://ibn.fm/2YLuF). “This was by far the hardest week emotionally because I do feel the progression of recovery, but racing requires an extreme physical and mental effort, and my body is not 100% able to sustain the intense race conditions.” Odyssey’s PRV-002 solution aims to eventually be approved for on-site administration at incidents where head injuries occur, such as at athletic competitions. Patients would be treated within the first minutes after the injury happens, allowing them to avoid swelling that might lead to long-term consequences. Currently there is no U.S. Food and Drug Administration (“FDA”)-approved medication for treating concussions, allowing Odyssey Health to state they are pursuing a novel solution to fulfill an unmet need for millions of people worldwide. The Phase II trial is expected to include military sites that sustain a high rate of concussion. “We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life,” Major General (Ret.) Jim Linder, the former chief of staff for the U.S. Special Operations Command, stated last month in addressing Odyssey’s testing program (https://ibn.fm/q3uBK).” For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

From Our Blog

Drone Detection and Vital Life Signs Monitoring Help Silynx’s In-Ear Tactical Communication Systems Support Those on the Front Lines

September 1, 2026

Whether you’re in the military, law enforcement, riot control, or other loud, chaotic, and potentially-dangerous industries, the ability to communicate with your team effectively, while also protecting your hearing, is critical. To address this growing need, Silynxcom Ltd. (NYSE American: SYNX) has developed exceptional in-ear tactical communication systems. Silynx offers these products to hundreds of […]

Rotate your device 90° to view site.